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Background: Over the past 25 years, African–Americans have experienced higher
rates of emergency department (ED) visits, hospitalizations, and death due to
asthma compared to other ethnic groups in the US. African–Americans of lower
socioeconomic groups are particularly vulnerable to asthma morbidity and mortality.
Few studies have investigated asthma-related healthcare services use by different
age and gender groups within this sub-population.
Objectives: The objectives of this study are to: (1) report rates of asthma among
African–Americans who receive healthcare through a state government Medicaid
program that provides medical coverage to low-income citizens; (2) report rates of
asthma-related medical services and prescription utilization for these recipients;
and (3) report the costs to the Medicaid program for asthma-related care for these
recipients.
Methods: This was a cross-sectional descriptive analysis. West Virginia (WV)
Medicaid administrative fee-for-service claims data from calendar year 2002 were
the data source. Medical services claims with a primary diagnosis of asthma for
recipients who were African–American less than 65 years of age were extracted.
Matching prescription claims for these recipients for medications to treat asthma
were extracted. Dollars reimbursed for medical services and prescription medica-
tions were from the perspective of WV Medicaid.
Results: There were 635 African–American recipients who had a primary diagnosis
of asthma. Children under 21 years of age comprised the majority of the sample.
Males under 21 years of age, and females 21 years and older had the highest rates of
asthma. Although males 21 years and older accounted for the lowest proportion of
age–gender groups, these recipients had the highest rates of hospitalizations and ED
visits for asthma. Less than one-third of the recipients had a prescription claim for anElsevier Ltd. All rights reserved.
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medications vs. controller pharmacotherapy for the sample. A majority of the dollars
paid by Medicaid for asthma care were for prescriptions and hospitalizations.
Conclusion: Asthma prevalence and asthma-related medical services utilization
rates among African–American recipients of Medicaid varied by age and gender
groups. These recipients appeared to be underutilizing controller pharmacotherapy
for asthma.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic disease of the airways that
causes recurrent and distressing episodes of wheez-
ing, breathlessness, chest tightness, and nighttime
or early morning coughing. In the US, the disease
affects approximately 20 million people, nearly 6
million of whom are under the age of 18 years.1
Asthma is often associated with substantial finan-
cial burdens2–4 and is a leading reason for utiliza-
tion of health services.5–7 Asthma accounts for an
estimated 14.5 million lost workdays for adults and
14 million lost school days for children in the US
annually.8 Additionally, asthma has been shown to
have a negative impact on a patient’s quality of
life,9 and psychological distress is common in
asthma.10
Surveillance reports over the last 20 years in the
US show that asthma has substantially impacted
African–Americans.8 In 2000, asthma prevalence
rates were higher among African–Americans (8.5%)
compared to Whites (7.1%).11 Hospitalization and
emergency department (ED) visit rates due to
asthma have been higher among African–American
children compared to White children.12–15 Dispa-
rities in mortality rates due to asthma among
African–Americans also have been reported, espe-
cially those of lower socioeconomic groups.15–19
Furthermore, it has been shown that low-income
individuals are more likely to miss or delay seeking
healthcare services.20
In 2003, the US Department of Health and Human
Services launched an initiative titled, ‘‘Steps to a
Healthier US’’.21 One purpose of the initiative is to
enhance access to health services by focusing on
those populations with the greatest needs. Asthma
was cited as a target disease because of its
debilitating effects and its responsiveness to pre-
vention measures. One method to identify and
target those groups in need where care may be
inadequate is to analyze the current prevalence of
asthma and treatments for asthma among vulner-
able or high-risk groups.
Despite the documented disparities among Afri-
can–Americans in terms of ED utilization andhospitalizations for asthma, little information ex-
ists regarding the age and gender differences in the
prevalence of asthma and prescription use for low-
income African–Americans. The purpose of this
paper is to report rates of medical services and
prescription utilization for asthma among African–
Americans who receive healthcare through the
State of West Virginia (WV) Medicaid program,
which provides medical coverage to low-income
citizens, as well as the costs to Medicaid for these
services.Methods
Data source
This study used computerized WV Medicaid paid
claims records for medical services and prescription
medications delivered through a fee-for-service
system between January 1 and December 31,
2002. Medicaid is a jointly funded program by the
US federal and state governments, and pays for
medical assistance of individuals and families with
low income and resources.22 The rules for counting
the income and resources vary from state to state.
For WV Medicaid, those individuals who receive
Supplementary Security Income automatically qua-
lify for benefits. The income of the applicant is
counted and compared to a federal poverty level
standard applicable to the size of the applicant’s
family. Similarly, resources of the applicant are also
counted to determine if the applicant meets the
resource threshold to be subsidy eligible. The
Department of Health and Human Resources
(DHHR) determines Medicaid eligibility at its local
administrative offices throughout the state.
The Medicaid data collected for this study
included claims paid for medical services and
prescription medications, as well as recipient
enrollment information. Data were de-identified
to prevent the investigators from identifying any
recipients in compliance with the West Virginia
University Institutional Review Board and Health
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(HIPAA) regulations that require the protection of
patient health information. The purpose of HIPAA is
to improve the efficiency and effectiveness of the
healthcare system by encouraging the development
of a health information system through the estab-
lishment of standards and requirements for the
electronic transmission of protected health
information.Study sample
In 2002, there were 58,909 African–American
residents in WV which accounted for 3.3% of the
state’s entire population. A total of 17,890 (30.4%)
received Medicaid benefits during the year. How-
ever, our target population consisted only of
recipients who were 64 years of age or younger
(n ¼ 16,667). Persons who were older than 64 years
of age were not included in the sample because the
elderly population in the US is insured under the
federal Medicare program. Medicare data were not
available for this study. From our target population,
those who had at least one medical services claim
for a hospitalization, ED, or office visit with a
primary diagnosis of asthma (using the Interna-
tional Classification of Diseases, 9th Edition, Clin-
ical Modification [ICD-9-CM] code 493.XX) were
selected for the study sample.Study design
This study used a cross-sectional design to conduct
a retrospective descriptive analysis of the preva-
lence of asthma, utilization of medical services and
prescription drugs for asthma, and related costs
incurred during 2002 among recipients of WV
Medicaid who were African–American. Costs for
healthcare services and prescription medications
were from the perspective of WV Medicaid. Dollars
reimbursed by Medicaid for hospitalizations were
not recorded in the claims data set used in this
study, so these particular costs were estimated
using US average diagnosis-related group (DRG)
reimbursement rates.23 The DRG is an inpatient or
hospital classification system used to pay a hospital
or other provider for services, and to categorize
illness by diagnosis and treatment. Costs for ED
visits, office visits, and prescription medications
were based on dollar amounts recorded in the
claims data set that equaled the actual amount
reimbursed by Medicaid for these services.Analysis
Medical services utilization
The frequency of visits for medical services for
asthma was based on what appeared to be the visits
associated with a particular episode of asthma or
an exacerbation of asthma for each recipient. For
example, if a recipient had claims for an ED visit
and hospitalization on the same date of service, it
was assumed that the recipient visited the ED and
was subsequently admitted to the hospital for that
particular episode of asthma. In such a circum-
stance, the event was counted only as a hospita-
lization, and the dollars paid by Medicaid for the
hospitalization were calculated as the sum of
dollars paid for both types of medical services.
Prescription utilization
Reviewing the utilization of prescription medica-
tions to treat asthma can serve as an indicator of
care for patients with asthma. Specifically, the
current prescription use patterns among the sample
will be compared to the ideal management of the
disease based on recommendations by the National
Heart, Lung, and Blood Institute (NHLBI). Guide-
lines published by the NHLBI recommend the use of
inhaled corticosteroids as the preferred controller
pharmacotherapy for patients with persistent
asthma.24
To report the patterns of asthma treatment
among the study sample, the proportion of reci-
pients who were treated by various pharmacother-
apy classes were calculated. Additionally, the
proportion of prescription claims paid by WV
Medicaid for the various pharmacotherapy classes
also was reported. Claims for prescription drugs
were categorized as either claims for quick-relief
or maintenance drugs. Quick-relief medications
included short-acting beta-agonists, anti-muscari-
nics, and oral corticosteroids. Maintenance drugs
included long-acting beta-agonists, leukotriene
inhibitors, methylxanthines, inhaled cromolyn, in-
haled nedocromil, and inhaled corticosteroids.Results
Study sample
Of the 16,667 African–Americans who comprised
our target population, there were 635 recipients
who had at least one medical services claim
(whether for hospital, ED, or office visit) with a
primary diagnosis of asthma paid by WV Medicaid.
Of these recipients, 66% were children under 21
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females (53.7%) compared to males (45.8%). Males
under 21 years of age comprised a majority of the
total sample (38.6%), whereas males over 20 years
of age accounted for the lowest proportion of the
total sample (7.2%). There were similar proportions
of females under 21 years of age (27.2%) and
females over 20 years of age (26.5%).
The overall rate of asthma was 38.1 per 1000
African–American recipients of WV Medicaid. Re-
cipients between 21 and 64 years of age had a
higher rate of asthma (40.1 per 1000) compared to
recipients less than 21 years of age (37.2 per 1000).
Recipients who were male had a higher rate of
asthma (40.5 per 1000) compared to recipients who
were female (36.0 per 1000). The highest rates for
asthma occurred among African–American recipi-
ents aged 21 and older who were female (43.2 per
1000), and African–American recipients less than 21
years of age who were male (43.1 per 1000). The
total numbers, proportions, and rates of asthma
among African–American recipients classified by
age and gender groups are presented in Table 1.
Medical services utilization
There was a total of 47 hospitalizations, 275 ED
visits, and 1075 office visits with a primary
diagnosis of asthma made by the study sample.Table 1 Numbers and rates of African–American recipien
age and gender groups.
Category Recipients with
(% in total)
Age
Children (0–20 years) 419 (66.0)
Adults (21–64 years) 216 (34.0)
Gender
Males 291 (45.8)
Females 341 (53.7)
Unknownz 3 (0.5)
Age and gender groups
Male children 245 (38.6)
Female children 173 (27.2)
Adult males 46 (7.2)
Adult females 168 (26.5)
Unknownz 3 (0.5)
Total 635 (100.0)
Rates based on the total number of African–Americans less t
benefits in 2002 (total N ¼ 16,667).
yDenominators used to calculate rates of asthma included recip
did not include managed care claims.
zRates unable to be calculated due to lack of population denomThe overall rates for asthma-related medical
services utilization among the population of Afri-
can–American recipients of WV Medicaid benefits
were as follows: 28.2 hospitalizations per 10,000
African–American recipients, 165.0 ED visits per
10,000 African–American recipients, and 64.5
office visits per 1000 African–American recipients.
Adults between 21 and 64 years of age had higher
medical services utilization rates compared to
children and adolescents under 21 years of age.
Rates of medical services utilization were higher
among recipients who were male than rates among
recipients who were female.
Recipients who were male between 21 and 64
years of age had the highest rate of hospitalizations
compared to other age and gender groups. The
rates of ED visits among males between 21 and 64
years of age were substantially higher compared to
the rates among females between 21 and 64 years
of age as well as the rates of ED visits among
children. Recipients who were female between
21 and 64 years of age had the highest rate of
office visits for asthma, followed by recipients who
were male and under 21 years of age. The lowest
rates of medical services utilization occurred
among recipients who were female and under 21
years of age. The rates of healthcare services
utilization by gender and age groups are shown in
Table 2.ts of West Virginia Medicaid with asthma classified by
asthma N Asthma rate per 1000,y
37.2
40.1
40.5
36.0
—
43.1
30.9
30.5
43.2
—
38.1
han 65 years of age in West Virginia who received Medicaid
ients enrolled in managed care plans, although the analyses
inators.
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Table 2 Rates of asthma-related hospitalizations, emergency department visits, and office visits among
African–American recipients of West Virginia Medicaid by age and gender groups.,y
Category Hospitalization rate
per 10,000
ED visit rate per
10,000
Office visit rate per
1000
Age
Children (0–20 years) 24.0 145.5 55.8
Adults (21–64 years) 37.1 205.8 82.7
Gender
Males 33.4 198.9 68.4
Females 24.3 139.3 60.8
Age and gender groups
Male children 31.7 184.8 69.9
Female children 16.1 105.5 41.3
Adult males 39.8 252.3 63.1
Adult females 36.0 187.8 88.8
Total 28.2 165.0 64.5
Rates based on the number of visits divided by the number of African–Americans in West Virginia who received Medicaid
benefits in 2002 in each demographic category (total N ¼ 16,667).
yDenominators used to calculate asthma-related medical services utilization rates included recipients enrolled in managed
care plans, although the analyses did not include managed care claims.
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There was a total of 3637 prescription claims paid
by WV Medicaid for asthma-related medications for
the study sample. On average, there were nearly
six prescription claims per recipient during the
year, and the median number of prescription claims
per recipient was equal to 4.0. The largest
proportion of claims by pharmacotherapy category
was for short-acting beta-agonists (43.3%). Claims
for leukotriene inhibitors accounted for approxi-
mately one-fifth of the claims (19.5%), followed by
claims for oral steroids (13.9%), and claims for
inhaled corticosteroids (12.5%). Overall, there was
a greater percentage of prescription claims for
quick-relief medications (61.0%) than for mainte-
nance drugs (39.0%) among the sample.
Among the 635 African–American recipients
included in the study sample, a substantial majority
had at least one prescription claim for a short-
acting beta-agonist medication (78.6%). Approxi-
mately 40% of the sample had at least one claim for
an oral steroid. Less than a third of the recipients
had at least one claim for a leukotriene inhibitor
(30.7%) or inhaled corticosteroid (31.3%) during the
year. A greater percentage of children in our
sample had at least one prescription claim for an
inhaled corticosteroid (34.8%) compared to adults
(24.5%).
Recipients who used short-acting beta-agonists
had an average of 3.2 claims per recipient in 2002.Similarly, recipients who used leukotriene inhibi-
tors had an average of 3.6 claims per recipient. In
contrast, recipients who used inhaled steroids had
an average of only 2.3 claims per recipient during
the year. The utilization of prescription medica-
tions for asthma among the study sample is shown
in Table 3.Costs to Medicaid
Medical services
WV Medicaid paid on average $3409 per hospitali-
zation for African–Americans who were admitted
for asthma during 2002. Medicaid paid on average
$149 per ED visit, and $84 per office visit for asthma
for those in the study sample who used these
services. Table 4 lists the estimated amounts
reimbursed by WV Medicaid for asthma-related
medical services.Prescription medications
The total asthma-related prescription drug costs to
WV Medicaid equaled approximately $179,124, at
an average cost of $49 per prescription claim. On
average, the highest costs per prescription claim
for drugs to treat asthma were for inhaled
corticosteroids ($111.30 per claim). Even though
leukotriene inhibitors and inhaled corticosteroids
accounted for only one-third of all prescription
claims for asthma, these medications accounted
ARTICLE IN PRESS
Table 4 Dollars reimbursed by West Virginia Medicaid for asthma-related medical services utilized by
African–American recipients.
Healthcare service Total number of visits Total costsy ($) Mean cost per visit ($)
Hospitalization 47 160,243 3409.43
Emergency department 275 40,915 148.78
Office visits 1075 90,281 83.98
Total number of visits with a primary diagnosis of asthma.
yCost estimates for office and emergency department visits based on actual amounts paid by Medicaid. Hospitalization costs
were estimated using national average DRG reimbursements.
Table 3 Distribution of African–American recipients of West Virginia Medicaid with asthma and asthma-related
prescription drug claims by drug class.
Drug class Recipients
(% in total),y
Number of claims
(% in total)z
Average claims per
recipientz
Short-acting beta-agonists 499 (78.6) 1575 (43.3) 3.2
Oral steroids 256 (40.3) 505 (13.9) 2.0
Anti-muscarinics 52 (8.2) 139 (3.8) 2.7
Methylxanthines 27 (4.3) 124 (3.4) 4.6
Long-acting beta-agonists 36 (5.7) 99 (2.7) 2.8
Leukotriene inhibitors 195 (30.7) 710 (19.5) 3.6
Inhaled cromolyn or nedocromil 15 (2.4) 32 (0.9) 2.1
Inhaled corticosteroids 199 (31.3) 453 (12.5) 2.3
Total 635 (100.0) 3637 (100.0) 5.7
Number of recipients who had at least one prescription claim for a medication by pharmacotherapy class.
yColumn percent sums to more than 100 due to those recipients who had claims for medications in more than one
pharmacotherapy class.
zNumber of prescription claims for medications by pharmacotherapy class.
zAverage equals the number of claims divided by the number of recipients within each pharmacotherapy class.
V. Pawar, M.J. Smith1584for nearly 58% of the total dollars paid by WV
Medicaid for prescriptions to treat asthma. Claims
for short-acting beta-agonists accounted for nearly
27% of the total dollars paid by Medicaid for
asthma-related prescriptions. Table 5 shows the
distribution of dollars reimbursed by WV Medicaid
for asthma-related prescription claims by drug
class.Combined medical services and prescription
medications
The dollars reimbursed by WV Medicaid for both
asthma-related medical services and prescription
medications totaled approximately $470,563. A
majority of the dollars were for prescription drugs
to treat asthma (38.1%), followed by hospitaliza-
tions (34.1%), and office visits (19.2%). ED visits
accounted for the lowest proportion of total dollars
(8.7%).Discussion
Asthma increasingly is a public health issue in the
US especially among minority and low-income
groups. During the past 20 years, African–Amer-
icans have had the highest prevalence rates,
hospitalization rates, and ED visit rates for asthma
compared to other ethnic groups. This study
focuses on the recent prevalence rates of asthma
and asthma-related medical services and prescrip-
tion utilization for different age and gender groups
of low-income African–Americans who received
Medicaid benefits in WV.
A majority of the prior studies investigating
asthma surveillance have compared overall pre-
valence rates among various ethnic groups. Few
studies have reported asthma prevalence rates for
different age and gender categories within each
ethnic group, making it difficult to compare the
results from the sample of African–Americans in our
ARTICLE IN PRESS
Table 5 Dollars reimbursed by West Virginia Medicaid for asthma-related prescription medications utilized by
African–American recipients.
Drug class Number of claims
(% in total)
Total costs ($)
(% in total)y
Average cost per
claim ($)z
Short-acting beta-agonists 1575 (43.3) 47,594.52 (26.6) 30.22
Oral steroids 505 (13.9) 6002.76 (3.4) 11.89
Anti-muscarinics 139 (3.8) 10,664.73 (6.0) 76.72
Methylxanthines 124 (3.4) 2105.77 (1.2) 16.98
Long-acting beta-agonists 99 (2.7) 7213.45 (4.0) 72.86
Leukotriene inhibitors 710 (19.5) 52,995.81 (29.6) 74.64
Inhaled cromolyn or nedocromil 32 (0.9) 2146.64 (1.2) 67.08
Inhaled corticosteroids 453 (12.5) 50,400.44 (28.1) 111.30
Total 3637 (100.0) 179,124 (100.0) 49.25
Number of prescription claims for medications by pharmacotherapy class.
yDollars reimbursed by West Virginia Medicaid for claims for asthma-related prescription medications by pharmacotherapy
class.
zAverage equals the costs for medications divided by the number of claims within each pharmacotherapy class.
Asthma-related healthcare services 1585study to previous literature. One study conducted
by Lozano et al.25 reported an asthma prevalence
rate of 4% among children who were Black who
received Medicaid benefits in the urban area of
Seattle-Tacoma, which was similar to the rate of
3.7% among our sample of children who reside
mainly in rural settings. There was no literature
identified that reported asthma prevalence rates
specifically for African–American adults that could
be compared to our sample of adults.
When we estimated asthma prevalence by age
and gender, we found that asthma was more
prevalent among African–American children who
were male and African–American females who were
older than 20 years of age than other age and
gender groups. This finding is consistent with other
surveillance studies.26,27 However, we also found
overall that adults 21 years of age and older had a
slightly higher rate of asthma compared to chil-
dren, and that adults utilized medical services for
asthma at a greater rate compared to children. This
observation differs from conventional knowledge in
that asthma is more prevalent among children than
adults. Our finding may be due to the fact that
28.5% of the adults in our sample had concomitant
chronic obstructive pulmonary disease, making
them more severe and in need of more frequent
care compared to the children in the sample.
Another explanation for the high rate of medical
services use for asthma among the adults in our
sample may be attributed to a high prevalence of
smoking in WV.28 This may be an important factor to
consider, because cigarette smoke is a dangerous
and important source of indoor pollution that may
be an aggravating factor in asthma.29 Also, statis-
tics have reported that African–American men tendto smoke at a higher rate than White men (31.4%
vs. 27.6%), White women (24.4%), and African–
American women (22.7%).30
The observation that African–American adults
had higher rates of hospitalizations and ED visits for
asthma also suggests that these recipients were
more likely to receive episodic care for their
asthma compared to children. Although certain
behavioral or cultural factors may be possibly
related to this observation, further empirical
investigation will be necessary to capture specific
reasons for this finding.
Another finding in this study was that a low
proportion of African–Americans were receiving
inhaled corticosteroid therapy. Although the 1997
NHLBI Guidelines had been in print for 5 years at
the time the prescriptions included in our study
were written and filled, less than one-third of the
African–American recipients in our sample had at
least one prescription claim for an inhaled corti-
costeroid during 2002. Inadequate pharmacother-
apy of African–Americans compared with Whites
have been shown to exist in other studies and may
contribute to racial disparities in asthma-related
health outcomes. Krishnan et al.31 determined race
and sex differences in the consistency of care with
national asthma guidelines in managed care orga-
nizations. They found that fewer African–Amer-
icans than Whites reported care consistent with
recommendations of daily inhaled corticosteroid
use.
The results of this study also showed that
recipients who used inhaled corticosteroids were
utilizing the medications less frequently (2.3 mean
claims per recipient) compared to those who were
filling prescriptions for short-acting beta-agonists
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have important implications because our sample
was relying more on quick-relief medications than
controller drugs, which may lead to uncontrolled
exacerbations of asthma.
It should be noted that an update to the NHLBI
Guidelines was released in June 2002.23 The update
lists inhaled corticosteroids as the preferred phar-
macotherapy of all patients with persistent asth-
ma. The update also lists leukotriene antagonists
as an alternate therapy to inhaled corticosteroids
in the treatment of patients with mild persis-
tent asthma. In this study, the proportion of
recipients who had at least one claim for a
leukotriene inhibitor medication (30.7%) was ap-
proximately equal to the proportion of reci-
pients who had at least one claim for an inhaled
steroid (31.3%) during the year. This pattern may
reflect the increasing role that leukotriene modi-
fiers play in the pharmacotherapy of patients with
asthma.
Interestingly, recipients who had used leuko-
triene inhibitors were utilizing the medications
more frequently (3.6 mean claims per recipient)
than when recipients were using inhaled steroids
(2.3 mean claims per recipient). Perhaps this gives
some indication that African–Americans prefer oral
administration of medication to treat asthma
rather than inhaled dosage forms. Overall, how-
ever, it appeared that African–American recipients
were underutilizing controller pharmacotherapy for
the treatment of their asthma. This issue is
especially important with respect to outcomes that
have been associated with the adequate use of
controller medications, especially inhaled corticos-
teroids.
Previous research has shown that appropriate
daily use of inhaled corticosteroids results in a
reduction in ED visits and hospital admissions
related to asthma. Despite their documented
usefulness in asthma management, inhaled corti-
costeroids accounted for only about 13% of the
prescription claims for asthma medications in this
study. Inappropriate drug therapy and underutiliza-
tion of inhaled corticosteroids has been identified
as one factor of ineffective asthma management
that can lead to increased hospitalizations, ED
visits, and office visits for uncontrolled asthma.32,33
This may be reflected in the data in our study in
which only 24.5% of the adults had at least one
prescription claim for an inhaled corticosteroid.
This could be another reason why the adults in our
sample had high rates of ED visits and hospitaliza-
tions. Future research should investigate factors
that are related to the inappropriate utilization of
prescription medications for asthma such as physi-cian prescribing behavior and patient medication-
taking behavior.Limitations
When interpreting the results of this study, some
limitations should be considered. Claims data are
subject to data entry and coding errors. Recipients
who had been misdiagnosed with asthma during a
medical visit would have been included in the study
sample due to the data extraction criteria used in
this study. Also, the ICD-9-CM coding recorded in
the medical claims data did not enable the
investigators to classify a recipient by disease
severity. Thus, it is difficult to determine whether
recipients in this sample were utilizing what would
be considered appropriate vs. inappropriate phar-
macotherapy to treat asthma at a given point in
time.
The recipients included in this study were
enrolled in a fee-for-service payment system in
Medicaid. Data for recipients enrolled in managed
care plans were not analyzed and therefore are not
represented in the present sample. The rates of
asthma and medical services utilization rates for
asthma reported in this study may underestimate
the true rate of disease among recipients of WV
Medicaid who are African–American.Conclusions
Patterns of asthma and asthma-related medical
services utilization varied by age and gender groups
among recipients of WV Medicaid who were
African–American. Rates of asthma were greatest
among children who were male and among adults
who were female. Adult recipients who were male
appeared to utilize medical services for episodic
care (hospitalizations and emergency department
visits) at a higher rate compared to other age and
gender groups.
Recipients of WV Medicaid who were African–A-
merican appeared to be underutilizing controller
pharmacotherapy for asthma. Only 31% of the
recipients had at least one prescription claim for
an inhaled corticosteroid during the year, and on
average recipients were filling more prescriptions
for short-acting beta-agonists than for inhaled
steroids. With regard to controller pharmacother-
apy utilization, recipients who used leukotriene
modifiers had filled more prescriptions on average
for these agents compared to recipients who used
inhaled corticosteroids.
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medical services and prescription medications for
asthma that were utilized by recipients who were
African–American. A majority of these dollars were
for prescription drugs and hospitalizations.Acknowledgments
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